Company / Cash & Equivalents
Acadia Pharmaceuticals Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$177.7M
FY2025
5-year range
$114.8M / $319.6M
FY2021-FY2025
Trend
-44.4%
vs FY2024
Sector context
#96 of 207
Health Care
What the data says
At $178M, Acadia Pharmaceuticals's cash & equivalents ranks #96 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $69M in FY2017 to $326M in FY2020.
Based on SEC 10-K filings.
$178M in FY2025 with a 5-year CAGR of -11.4%.
Declined from $189M to $178M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +15.7%
- 5-Year CAGR
- -11.4%
- 10-Year CAGR
- -
Sector benchmark
#96 of 207 in Health CareTop 46% of 207This company $177.7M Sector average $669.5M
▼
-73.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 44.4% year-over-year.
- Ranks #96 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $177.7M | -44.4% |
| FY2024 | $319.6M | +69.4% |
| FY2023 | $188.7M | +64.3% |
| FY2022 | $114.8M | -22.1% |
| FY2021 | $147.4M | -54.8% |
| FY2020 | $326.0M | +71.9% |
| FY2019 | $189.7M | +40.8% |
| FY2018 | $134.8M | +94.1% |
| FY2017 | $69.4M | -57.6% |
| FY2016 | $163.6M | +60.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026